Baird Financial Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $514M | Buy |
2,042,445
+92,242
| +5% | +$19.8M | 0.71% | 35 |
|
|
2026
Q1 | $424M | Sell |
1,950,203
-23,182
| -1% | -$5.14M | 0.66% | 37 |
|
|
2025
Q4 | $451M | Sell |
1,973,385
-22,096
| -1% | -$5.03M | 0.7% | 37 |
|
|
2025
Q3 | $462M | Buy |
1,995,481
+8,141
| +0.4% | +$1.66M | 0.74% | 32 |
|
|
2025
Q2 | $369M | Sell |
1,987,340
-36,202
| -2% | -$6.73M | 0.65% | 34 |
|
|
2025
Q1 | $424M | Sell |
2,023,542
-57,053
| -3% | -$11.1M | 0.82% | 29 |
|
|
2024
Q4 | $370M | Sell |
2,080,595
-31,647
| -1% | -$5.82M | 0.71% | 33 |
|
|
2024
Q3 | $417M | Sell |
2,112,242
-18,369
| -0.9% | -$3.43M | 0.81% | 25 |
|
|
2024
Q2 | $365M | Sell |
2,130,611
-26,898
| -1% | -$4.46M | 0.76% | 28 |
|
|
2024
Q1 | $393M | Buy |
2,157,509
+61,842
| +3% | +$10.7M | 0.82% | 27 |
|
|
2023
Q4 | $325M | Buy |
2,095,667
+12,389
| +0.6% | +$1.81M | 0.74% | 23 |
|
|
2023
Q3 | $311M | Sell |
2,083,278
-37,109
| -2% | -$5.45M | 0.85% | 18 |
|
|
2023
Q2 | $286M | Sell |
2,120,387
-264,013
| -11% | -$38.7M | 0.75% | 21 |
|
|
2023
Q1 | $380M | Buy |
2,384,400
+23,768
| +1% | +$3.63M | 0.94% | 18 |
|
|
2022
Q4 | $382M | Sell |
2,360,632
-439,055
| -16% | -$67.3M | 1% | 18 |
|
|
2022
Q3 | $376M | Sell |
2,799,687
-344,486
| -11% | -$49.4M | 1.11% | 13 |
|
|
2022
Q2 | $482M | Sell |
3,144,173
-102,798
| -3% | -$15.7M | 1.34% | 11 |
|
|
2022
Q1 | $526M | Buy |
3,246,971
+33,492
| +1% | +$4.87M | 1.3% | 12 |
|
|
2021
Q4 | $435M | Buy |
3,213,479
+22,876
| +0.7% | +$2.7M | 1.02% | 13 |
|
|
2021
Q3 | $344M | Buy |
3,190,603
+21,610
| +0.7% | +$2.47M | 0.88% | 15 |
|
|
2021
Q2 | $357M | Buy |
3,168,993
+11,928
| +0.4% | +$1.34M | 0.93% | 15 |
|
|
2021
Q1 | $342M | Buy |
3,157,065
+33,276
| +1% | +$3.56M | 0.96% | 14 |
|
|
2020
Q4 | $335M | Buy |
3,123,789
+81,305
| +3% | +$7.81M | 1% | 14 |
|
|
2020
Q3 | $266M | Sell |
3,042,484
-46,566
| -2% | -$4.38M | 0.91% | 17 |
|
|
2020
Q2 | $303M | Buy |
3,089,050
+193,458
| +7% | +$17M | 1.14% | 14 |
|
|
2020
Q1 | $221M | Sell |
2,895,592
-13,793
| -0.5% | -$1.17M | 1.01% | 14 |
|
|
2019
Q4 | $258M | Buy |
2,909,385
+125,945
| +5% | +$10.5M | 0.92% | 15 |
|
|
2019
Q3 | $211M | Buy |
2,783,440
+119,496
| +4% | +$8.19M | 0.83% | 17 |
|
|
2019
Q2 | $194M | Buy |
2,663,944
+832,875
| +45% | +$65.5M | 0.75% | 22 |
|
|
2019
Q1 | $148M | Buy |
1,831,069
+24,932
| +1% | +$2.04M | 0.86% | 14 |
|
|
2018
Q4 | $167M | Buy |
1,806,137
+393,186
| +28% | +$34.6M | 1.13% | 10 |
|
|
2018
Q3 | $134M | Sell |
1,412,951
-271,470
| -16% | -$25.7M | 0.84% | 13 |
|
|
2018
Q2 | $156M | Buy |
1,684,421
+118,903
| +8% | +$11.6M | 1.06% | 10 |
|
|
2018
Q1 | $148M | Sell |
1,565,518
-126,739
| -7% | -$13.9M | 1.04% | 9 |
|
|
2017
Q4 | $164M | Sell |
1,692,257
-53,454
| -3% | -$5.04M | 1.16% | 9 |
|
|
2017
Q3 | $155M | Sell |
1,745,711
-183,767
| -10% | -$14M | 1.17% | 8 |
|
|
2017
Q2 | $140M | Sell |
1,929,478
-425,893
| -18% | -$28.6M | 1.1% | 11 |
|
|
2017
Q1 | $153M | Buy |
2,355,371
+63,933
| +3% | +$4.02M | 1.24% | 9 |
|
|
2016
Q4 | $143M | Buy |
2,291,438
+283,099
| +14% | +$17.3M | 1.25% | 10 |
|
|
2016
Q3 | $127M | Sell |
2,008,339
-175,324
| -8% | -$11.3M | 1.13% | 11 |
|
|
2016
Q2 | $137M | Sell |
2,183,663
-54,686
| -2% | -$3.33M | 1.26% | 9 |
|
|
2016
Q1 | $128M | Buy |
2,238,349
+64,610
| +3% | +$3.6M | 1.22% | 9 |
|
|
2015
Q4 | $129M | Buy |
2,173,739
+66,758
| +3% | +$3.85M | 1.29% | 9 |
|
|
2015
Q3 | $115M | Buy |
2,106,981
+21,948
| +1% | +$1.43M | 1.22% | 8 |
|
|
2015
Q2 | $140M | Buy |
+2,085,033
| New | +$136M | 1.38% | 5 |
|
Other funds holding ABBV
Baird Financial Group's ABBV Position: Q2 2026 in Review
Baird Financial Group increased its AbbVie (ABBV) stake by 4.7% in Q2 2026, buying an estimated $19.8M and bringing the position to 2,042,445 shares worth $514M. The position accounts for 0.71% of the portfolio, ranked #35.
Baird Financial Group first reported a position in ABBV in Q2 2015 and has held it in 45 quarters since. The position peaked at $526M in Q1 2022. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Baird Financial Group held 2,042,445 shares of AbbVie worth $514M as of Q2 2026.
- Baird Financial Group bought 92,242 AbbVie shares in Q2 2026, an estimated $19.8M.
- AbbVie made up 0.71% of Baird Financial Group's portfolio in Q2 2026, its #35 holding.
- Baird Financial Group first reported a position in AbbVie in Q2 2015 and has held it in 45 quarters since.
- Baird Financial Group's AbbVie position peaked at $526M in Q1 2022.
- 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.